L'impiego della tossina botulinica tipo A nel trattamento della dissinergia detrusore sfintere

F. Beleggia; E. Beccia; E. Imbriani; M. Basciani; D. Intiso; R. Cioffi; P. Simone; V. Ricci Barbini

L'impiego della tossina botulinica tipo A nel trattamento della dissinergia detrusore sfintere

Translated title of the contribution: The use of botulinum A toxin (BTX) in the treatment of detrusor-spincter dyssynergia

F. Beleggia, E. Beccia, E. Imbriani, M. Basciani, D. Intiso, R. Cioffi, P. Simone, V. Ricci Barbini

IRCCS Casa Sollievo della Sofferenza

Research output: Contribution to journal › Article › peer-review

Abstract

The detrusor-sphincter dyssynergia (DSD) is a common and significant problem for patients with spinal cord lesions. If not treated, DSD can lead to severe and potentially lethal complications (urinary tract infections and renal damage). BTX inhibits acetylcholine release at the neuromuscular junction, producing muscle chemical denervation in the site of injection. The aim of this preliminar study was to test the safety and the effects of BTX injection in the spastic urethral rhabdosphincter in patients with DSD. Five patients (3 M, 2 F; mean age 43 years, range 22-56) with DSD entered the study. Videourodynamic parameters were controlled before BTX injection at 10 days, at 3 and 6 months after infiltration. The aim of this preliminary study was to test the safety and the effects of BTX infection in the spastic urethral rhabdosphincter in patients with DSD. The post void residual urine volume, the maximum pressure of emptying and the maximum pressure of urethral closure are reported in Tab. II-III-IV. Patients reported subjective improvement of bladder emptying and improved quality of life. No adverse effects related to pharmacological activity of BTX or to infiltration procedures were observed.

Translated title of the contribution	The use of botulinum A toxin (BTX) in the treatment of detrusor-spincter dyssynergia
Original language	Italian
Pages (from-to)	61-63
Number of pages	3
Journal	Archivio Italiano di Urologia e Andrologia
Volume	69
Issue number	1 SUPPL.
Publication status	Published - 1997

ASJC Scopus subject areas

Nephrology
Urology

Fingerprint Dive into the research topics of 'The use of botulinum A toxin (BTX) in the treatment of detrusor-spincter dyssynergia'. Together they form a unique fingerprint.

Cite this

@article{2f23450792bc43768c62503fac86f3ab,

title = "L'impiego della tossina botulinica tipo A nel trattamento della dissinergia detrusore sfintere",

abstract = "The detrusor-sphincter dyssynergia (DSD) is a common and significant problem for patients with spinal cord lesions. If not treated, DSD can lead to severe and potentially lethal complications (urinary tract infections and renal damage). BTX inhibits acetylcholine release at the neuromuscular junction, producing muscle chemical denervation in the site of injection. The aim of this preliminar study was to test the safety and the effects of BTX injection in the spastic urethral rhabdosphincter in patients with DSD. Five patients (3 M, 2 F; mean age 43 years, range 22-56) with DSD entered the study. Videourodynamic parameters were controlled before BTX injection at 10 days, at 3 and 6 months after infiltration. The aim of this preliminary study was to test the safety and the effects of BTX infection in the spastic urethral rhabdosphincter in patients with DSD. The post void residual urine volume, the maximum pressure of emptying and the maximum pressure of urethral closure are reported in Tab. II-III-IV. Patients reported subjective improvement of bladder emptying and improved quality of life. No adverse effects related to pharmacological activity of BTX or to infiltration procedures were observed.",

keywords = "botulinum A toxin, detrusor spincter dyssynergia",

author = "F. Beleggia and E. Beccia and E. Imbriani and M. Basciani and D. Intiso and R. Cioffi and P. Simone and {Ricci Barbini}, V.",

year = "1997",

language = "Italian",

volume = "69",

pages = "61--63",

journal = "Archivio Italiano di Urologia Nefrologia Andrologia",

issn = "1120-8538",

publisher = "Edizioni Scripta Manent s.n.c.",

number = "1 SUPPL.",

}

TY - JOUR

T1 - L'impiego della tossina botulinica tipo A nel trattamento della dissinergia detrusore sfintere

AU - Beleggia, F.

AU - Beccia, E.

AU - Imbriani, E.

AU - Basciani, M.

AU - Intiso, D.

AU - Cioffi, R.

AU - Simone, P.

AU - Ricci Barbini, V.

PY - 1997

Y1 - 1997

N2 - The detrusor-sphincter dyssynergia (DSD) is a common and significant problem for patients with spinal cord lesions. If not treated, DSD can lead to severe and potentially lethal complications (urinary tract infections and renal damage). BTX inhibits acetylcholine release at the neuromuscular junction, producing muscle chemical denervation in the site of injection. The aim of this preliminar study was to test the safety and the effects of BTX injection in the spastic urethral rhabdosphincter in patients with DSD. Five patients (3 M, 2 F; mean age 43 years, range 22-56) with DSD entered the study. Videourodynamic parameters were controlled before BTX injection at 10 days, at 3 and 6 months after infiltration. The aim of this preliminary study was to test the safety and the effects of BTX infection in the spastic urethral rhabdosphincter in patients with DSD. The post void residual urine volume, the maximum pressure of emptying and the maximum pressure of urethral closure are reported in Tab. II-III-IV. Patients reported subjective improvement of bladder emptying and improved quality of life. No adverse effects related to pharmacological activity of BTX or to infiltration procedures were observed.

AB - The detrusor-sphincter dyssynergia (DSD) is a common and significant problem for patients with spinal cord lesions. If not treated, DSD can lead to severe and potentially lethal complications (urinary tract infections and renal damage). BTX inhibits acetylcholine release at the neuromuscular junction, producing muscle chemical denervation in the site of injection. The aim of this preliminar study was to test the safety and the effects of BTX injection in the spastic urethral rhabdosphincter in patients with DSD. Five patients (3 M, 2 F; mean age 43 years, range 22-56) with DSD entered the study. Videourodynamic parameters were controlled before BTX injection at 10 days, at 3 and 6 months after infiltration. The aim of this preliminary study was to test the safety and the effects of BTX infection in the spastic urethral rhabdosphincter in patients with DSD. The post void residual urine volume, the maximum pressure of emptying and the maximum pressure of urethral closure are reported in Tab. II-III-IV. Patients reported subjective improvement of bladder emptying and improved quality of life. No adverse effects related to pharmacological activity of BTX or to infiltration procedures were observed.

KW - botulinum A toxin

KW - detrusor spincter dyssynergia

UR - http://www.scopus.com/inward/record.url?scp=0030998959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030998959&partnerID=8YFLogxK

M3 - Articolo

C2 - 9181925

AN - SCOPUS:0030998959

VL - 69

SP - 61

EP - 63

JO - Archivio Italiano di Urologia Nefrologia Andrologia

JF - Archivio Italiano di Urologia Nefrologia Andrologia

SN - 1120-8538

IS - 1 SUPPL.

ER -